Department of Nuclear Medicine, Ren Ji Hospital was established in 1958. It is a research-oriented clinical professional discipline integrating imaging diagnosis, functional testing, radionuclide therapy, in vitro analysis, and new drug development and production. It is the first batch of domestic master's and doctoral degree-granting sites and mobile post-doctoral research stations for Imaging and Nuclear Medicine, the affiliated department of the Institute of Clinical Nuclear Medicine of Shanghai Jiao Tong University School of Medicine, the Clinical Pharmacology Base of Ren Ji Hospital Drug Research Institute (Nuclear Medicine), Radiopharmaceuticals (Category IV) License Laboratory, "Key Discipline" of Shanghai Municipal Education Commission, "First-Class Discipline" of Shanghai, "Plateau Discipline" of Shanghai, National Key Clinical Specialty of Medical Imaging. It has been ranked among the top ten for many years in the Fudan version of the Hospital Specialty Reputation Ranking and has topped the list of most competitive nuclear medicine specialties among Shanghai's Grade III Class A hospitals for three consecutive years.
Our department was the first batch to introduce PET/CT imaging in China. We have completed tens of thousands of PET/CT examinations every year with high quality. PET/MR configuration license was obtained in 2019. In 2020, an innovative molecular imaging research and development center integrating "Production, Academy, and Medical Research"-- "Ren Ji-UIH Molecular Imaging Research and Development Center" was established. During 2020 to 2021, the world's cutting-edge nuclear medicine imaging equipment including μ-EXPLORER Total-body PET/CT and ultra-definition TOF PET/MR were successively introduced and installed.
We jointly carried out a variety of new positron molecular probe PET imaging technologies with clinical departments, such as 68Ga-PSMA, 68Ga-DOTATATE, 68Ga-FAPI, 11C-acetate, 11C-choline, 11C-methionine, 11C-CFT, 18F-AV133, 18F-AV45, 18F-PI2620, 18F-PBR06, 18F-NaF, which can be applied to the clinical diagnosis and research of tumor and nervous system diseases. We have undertaken a number of domestic and international multi-center clinical trials, with a high level of molecular imaging technology application and clinical translation capabilities. More than 20 SPECT clinical examination items such as renal dynamic imaging, myocardial blood perfusion (rest + stress) imaging, whole body bone scan, lung ventilation-perfusion imaging, were routinely performed. In addition, the basic research and clinical translation of 99mTc-PYP, 99mTc-RGD and other imaging agents have been carried out. We have a standard nuclide therapy protective ward, equipped with automatic drug dispensing and remote drug delivery system, and carries out treatment projects such as 131I therapy of hyperthyroidism and differentiated thyroid cancer, 89Sr or 223Ra therapy of bone metastatic cancer and 125I particle implantation.
The discipline construction has continued to make progress, and it has received fundings in succession from national key research and development programs and other national projects, and a number of high-quality academic papers have been published in top journals of medical imaging. The talent training has been fruitful, and many of the excellent young staff have been funded by talent programs such as Shanghai Youth Science and Technology Star, "Rising Stars of Medical Talent" Youth Development Program and Sailing Program.